Current status and new treatment approaches in TP53 mutated AML

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,780 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

Genomic classification and prognosis in acute myeloid leukemia

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · see citing works

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825 · see citing works

5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

Christman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,532 · see citing works

p53 Status and the Efficacy of Cancer Therapy in Vivo

Lowe, S. W., Bodis, S. B., McClatchey, A. I., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,470 · see citing works

Post-translational modification of p53 in tumorigenesis

Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270 · see citing works

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Kantarjian, H. M., Thomas, X., Dmoszyńska, A., Wierzbowska, A., Mazur, G. J., Mayer, J., Gau, J., Chou, W., Buckstein, R. J., Čermák, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,170 · see citing works

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165 · see citing works

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,031 · see citing works

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991 · see citing works

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961 · see citing works

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892 · see citing works

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796 · see citing works

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776 · see citing works

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734 · see citing works

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Hills, R. K., Castaigné, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S. H., Othus, M. K. D., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 722 · see citing works

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688 · see citing works

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

Rücker, F. G., Schlenk, R. F., Bullinger, L., Käyser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2011) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 680 · see citing works

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Daver, N. G., Garcia‐Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M. Y., Ravandi‐Kashani, F., Jabbour, E. J., Kadia, T. M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 562 · see citing works

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529 · see citing works

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · see citing works

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464 · see citing works

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

Blum, W. G., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S. M., Liu, S., Havelange, V., Becker, H., Schaaf, L. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450 · see citing works

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

Ritchie, D. S., Neeson, P. J., Khot, A. S., Peinert, S., Tai, T. Y., Tainton, K. M., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 442 · see citing works

p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression

Moon, S.-H., Huang, C., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp‐Hill, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 440 · see citing works

Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

de Lima, M., Giralt, S., Thall, P. F., Silva, L. D. P., Jones, R. B., Komanduri, K. V., Braun, T. M., Nguyen, H. Q., Champlin, R. E., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427 · see citing works

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

Wang, Q., Wang, Y., Lv, H., Han, Q., Fan, H., Guo, B., Wang, L.-L., & Han, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396 · see citing works

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

Hollenbach, P. W., Nguyen, A. N., Brady, H. A., Williams, M. M., Ning, Y., Richard, N., Krushel, L. A., Aukerman, S. L., Heise, C. C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 351 · see citing works

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348 · see citing works

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Baumeister, S. H. C., Murad, J., Werner, L. L., Daley, H., Trebeden‐Negre, H., Gicobi, J. K., Schmucker, A. C., Reder, J., Sentman, C. L., Gilham, D. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0307 · Cited by 331 · see citing works

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330 · see citing works

Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis

Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · see citing works

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

Li, D., Marchenko, N. D., Schulz‐Heddergott, R., Fischer, V., Velasco-Hernández, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 298 · see citing works

The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.

Eliopoulos, A. G., Kerr, R. S., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., & Young, L. S. (1995) · PubMed · Cited by 296 · see citing works

Implications of the p53 tumor-suppressor gene in clinical oncology.

Chang, F., Syrjänen, S., & Syrjänen, K. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.1009 · Cited by 264 · see citing works

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G. M., Jabbour, E. J., Konopleva, M. Y., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261 · see citing works

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation

Porta, M. G. D., Gallì, A., Bacigalupo, A. P., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., Lint, M. T. V., Pioltelli, P. E., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 255 · see citing works

A novel hierarchical prognostic model of AML solely based on molecular mutations

Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C., Staib, P., Serve, H. L., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419622 · Cited by 252 · see citing works

<i> <scp>TP</scp> 53 </i> mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250 · see citing works

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247 · see citing works

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

Parrales, A., Ranjan, A., Iyer, S. V., Padhyé, S., Weir, S. J., Roy, A., & Iwakuma, T. (2016) · Nature Cell Biology · doi:10.1038/ncb3427 · Cited by 239 · see citing works

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231 · see citing works

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Lübbert, M., Rüter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 230 · see citing works

Genetics of therapy-related myelodysplasia and acute myeloid leukemia

Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 230 · see citing works

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 224 · see citing works

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

Bowen, D., Groves, M. J., Burnett, A. K., Patel, Y., Allen, C. G., Green, C. L., Gale, R. E., Hills, R. K., & Linch, D. C. (2008) · Leukemia · doi:10.1038/leu.2008.173 · Cited by 214 · see citing works

Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 188 · see citing works

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

Schoch, C., Kern, W., Kohlmann, A., Hiddemann, W., Schnittger, S., & Haferlach, T. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20193 · Cited by 188 · see citing works

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

Craddock, C., Jilani, N., Siddique, S., Yap, C., Khan, J., Nagra, S., Ward, J., Ferguson, P., Hazlewood, P., Buka, R. J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.09.004 · Cited by 177 · see citing works

Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial

Budde, L. E., Song, J. Y., Kim, Y., Blanchard, S., Wagner, J. R., Stein, A. S., Weng, L., Real, M. M. D., Hernandez, R., Marcucci, E. C., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.811.811 · Cited by 176 · see citing works

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution

Hou, H.-A., Chou, W.-C., Kuo, Y.-Y., Liu, C.-Y., Lin, L., Tseng, M.-H., Chiang, Y.-C., Liu, M.-C., Liu, C.-W., Tang, J.-L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.59 · Cited by 165 · see citing works

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Pusic, I., Choi, J., Fiala, M. A., Gao, F., Holt, M. S., Cashen, A. F., Vij, R., Abboud, C. N., Stockerl-Goldstein, K. E., Jacoby, M. A., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.026 · Cited by 164 · see citing works

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance

Martirosyan, A., Clendening, J. W., Goard, C. A., & Penn, L. Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-103 · Cited by 160 · see citing works

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

Seifert, H., Mohr, B., Thiede, C., Oelschlägel, U., Schäkel, U., Illmer, T., Soucek, S., Ehninger, G., Schaich, M. A., & on behalf of the Study Alliance Leukemia (SAL) (2009) · Leukemia · doi:10.1038/leu.2008.375 · Cited by 158 · see citing works

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Peng, J., Tang, G., Goswami, M., Young, K. H., Singh, R. R., Medeiros, L. J., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0139-z · Cited by 141 · see citing works

First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

Liu, F., Cao, Y., Pinz, K. G., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C. O., Su, Y., et al. (2018) · Blood · doi:10.1182/blood-2018-99-110579 · Cited by 141 · see citing works

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140 · see citing works

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.160 · Cited by 139 · see citing works

Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Issa, J. J., Garcia‐Manero, G., Huang, X., Cortes, J. E., Ravandi, F., Jabbour, E. J., Borthakur, G. M., Brandt, M., Pierce, S. A., & Kantarjian, H. M. (2014) · Cancer · doi:10.1002/cncr.29085 · Cited by 139 · see citing works

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Döhner, H., Dolnik, A., Tang, L., Seymour, J. F., Minden, M. D., Stone, R. M., Bernal, T., Al‐Ali, H. K., Santini, V., Vyas, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0257-z · Cited by 132 · see citing works

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

Kirschbaum, M. H., Gojo, I., Goldberg, S. L., Bredeson, C., Kujawski, L. A., Yang, A. S., Marks, P. W., Frankel, P. H., Sun, X. G., Tosolini, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13016 · Cited by 131 · see citing works

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126 · see citing works

Mutations of the P53 gene in acute myeloid leukaemia

Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Laı̈, J. L., Vanrumbeke, M., Loucheux‐Lefebvre, M. H., Bauters, F., Berger, R., & Kerckaert, J. P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08897.x · Cited by 117 · see citing works

Immunohistochemical correlates of TP53 somatic mutations in cancer

Murnyák, B., & Hortobágyi, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11912 · Cited by 116 · see citing works

Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers

Hamada, M., Fujiwara, T., HIZUTA, A., Gochi, A., Naomoto, Y., Takakura, N., Takahashi, K., Roth, J. A., Tanaka, N., & Orita, K. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01220804 · Cited by 115 · see citing works

Acute Myeloid Leukemia: The Good, the Bad, and the Ugly

Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 111 · see citing works

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Cummins, K. D., Frey, N. V., Nelson, A. M., Schmidt, A. H., Luger, S. M., ISAACS, R. E., Lacey, S. F., Hexner, E. O., Melenhorst, J. J., June, C. H., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1359.1359 · Cited by 111 · see citing works

Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer

Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 108 · see citing works

TP 53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 98 · see citing works

Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

Prébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 96 · see citing works

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Craddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88 · see citing works

Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms

Au, C. H., Wa, A., Ho, D. N. Y., Chan, T. L., & Ma, E. S. K. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0456-8 · Cited by 86 · see citing works

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Bug, G., Burchert, A., Wagner, E.-M., Kröger, N. M., Berg, T., Gueller, S., Metzelder, S., Wolf, A., Hünecke, S., Bader, P., et al. (2017) · Leukemia · doi:10.1038/leu.2017.242 · Cited by 85 · see citing works

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 85 · see citing works

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84 · see citing works

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

Baldwin, A. E., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M. R., Li, W., Harlow, E., & Münger, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007462107 · Cited by 83 · see citing works

The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine

Nieto, M. D., Samper, E., Fraga, M. F., de Buitrago, G. G., Esteller, M., & Serrano, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207175 · Cited by 83 · see citing works

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion

Sebaa, A., Adès, L., Baran‐Marszak, F., Mozziconacci, J., Penther, D., Dobbelstein, S., Stamatoullas, A., Récher, C., Prébet, T., Moulessehoul, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21993 · Cited by 81 · see citing works

Role ofASXL1andTP53mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes

Devillier, R., Mas, V. M., Gelsi‐Boyer, V., Demur, C., Murati, A., Corre, J., Prébet, T., Bertoli, S., Brecqueville, M., Arnoulet, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3460 · Cited by 81 · see citing works

Molecularly targeted therapies for p53-mutant cancers

Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 81 · see citing works

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

Sallman, D. A., Brayer, J. B., Sagatys, E. M., Lonez, C., Breman, E., Agaugué, S., Verma, B., Gilham, D. E., Lehmann, F. F., & Davila, M. L. (2018) · Haematologica · doi:10.3324/haematol.2017.186742 · Cited by 81 · see citing works

TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers

Győrffy, B., Bottai, G., Lehmann‐Che, J., Kéri, G., Őrfi, L., Iwamoto, T., Desmedt, C., Bianchini, G., Turner, N. C., de Thé, H., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.018 · Cited by 80 · see citing works

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

Origanti, S., Cai, S.-R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013) · Oncogene · doi:10.1038/onc.2012.84 · Cited by 74 · see citing works

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Ali, D., Jönsson‐Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01557.x · Cited by 70 · see citing works

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

McGraw, K. L., Nguyen, J., Komrokji, R. S., Sallman, D. A., Ali, N. H. A., Padron, E., Lancet, J. E., Moscinski, L. C., List, A. F., & Zhang, L. (2016) · Haematologica · doi:10.3324/haematol.2016.143214 · Cited by 68 · see citing works

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Garcia‐Manero, G., Sasaki, K., Bravo, G. M., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119424 · Cited by 68 · see citing works

Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Sallman, D. A., Dezern, A. E., Steensma, D. P., Sweet, K. L., Cluzeau, T., Sekeres, M. A., Garcia‐Manero, G., Roboz, G. J., McLemore, A. F., McGraw, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119990 · Cited by 66 · see citing works

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis

Fernandez‐Pol, S., Ma, L., Ohgami, R. S., & Arber, D. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.206 · Cited by 64 · see citing works

PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

Nahi, H., Merup, M., Lehmann, S., Bengtzén, S., Möllgård, L., Selivanova, G., Wiman, K. G., & Paul, C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05851.x · Cited by 62 · see citing works

Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?

Tasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 59 · see citing works

Decitabine inTP53-Mutated AML

Welch, J. S., Petti, A. A., & Ley, T. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616062 · Cited by 56 · see citing works

A targeted next‐generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice

Lin, P., Li, H., Fan, S., Yuan, T., Chen, M., Hsu, Y., Yang, Y., Li, L., Yeh, S., Bai, L., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.969 · Cited by 53 · see citing works

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

Goldberg, A. D., Talati, C., Desai, P. M., Famulare, C. A., Devlin, S. M., Farnoud, N. R., Sallman, D. A., Lancet, J. E., Roboz, G. J., Sweet, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117772 · Cited by 44 · see citing works

Acute myeloid leukemia targets for bispecific antibodies

Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.2 · Cited by 44 · see citing works

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

Kadia, T. M., Cortes, J. E., Ghorab, A., Ravandi, F., Jabbour, E. J., Daver, N. G., Alvarado, Y., Ohanian, M. N., Konopleva, M. Y., & Kantarjian, H. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7014 · Cited by 43 · see citing works

Erratum: Acute myeloid leukemia targets for bispecific antibodies

Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.35 · Cited by 38 · see citing works

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells

Yi, L., Sun, Y., & Levine, A. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2441 · Cited by 37 · see citing works

Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells

Nishioka, C., Ikezoe, T., Yang, J., Udaka, K., & Yokoyama, A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.04.004 · Cited by 34 · see citing works

TP53 mutations in older adults with acute myeloid leukemia

Yanada, M., Yamamoto, Y., Iba, S., Okamoto, A., Inaguma, Y., Tokuda, M., Morishima, S., Kanie, T., Mizuta, S., Akatsuka, Y., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1942-1 · Cited by 34 · see citing works

Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Oran, B., Lima, M. J. G. D., Garcia‐Manero, G., Thall, P. F., Lin, R., Alousi, A. M., Hosing, C. M., Kebriaei, P., Popat, U., Giralt, S. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111582 · Cited by 31 · see citing works

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors

Ungerstedt, J. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103091 · Cited by 30 · see citing works

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Sallman, D. A., Kerre, T. C. C., Poiré, X., Havelange, V., Lewalle, P., Davila, M. L., Wang, E. S., Dekker, D., Snykers, S., Sotiropoulou, P. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111326 · Cited by 26 · see citing works

Statins induce lethal effects in acute myeloblastic leukemia cells within 72 hours

Burke, L. P., & Kukoly, C. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701760011 · Cited by 25 · see citing works

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

Min, C., Moore, N., Shearstone, J. R., Quayle, S. N., Huang, P., van Duzer, J. H., Jarpe, M. B., Jones, S. S., & Yang, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169128 · Cited by 24 · see citing works

Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor

Terada, K., Yamaguchi, H., Ueki, T., Usuki, K., Kobayashi, Y., Tajika, K., Gomi, S., Kurosawa, S., Miyadera, K., Tokura, T., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3143-2 · Cited by 17 · see citing works

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

Daver, N. G., Garcia‐Manero, G., Basu, S., Cortes, J. E., Ravandi, F., Kadia, T. M., Konopleva, M. Y., Jabbour, E. J., Dinardo, C. D., Assi, R. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-120157 · Cited by 16 · see citing works

Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Garcia‐Manero, G., Bravo, G. M., Sasaki, K., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118948 · Cited by 14 · see citing works

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

Sallman, D. A., Al Ali, N., Yun, S., Padron, E., Song, J., Hussaini, M. O., Talati, C., Sweet, K. L., Lancet, J. E., List, A. F., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117297 · Cited by 12 · see citing works

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Wong, E. Y. L., Dawson, E., Davis, J. E., Koldej, R. M., Ludford‐Menting, M., Lansdown, M., Lambie, H., Szer, J., Grigg, A., & Ritchie, D. (2018) · Blood · doi:10.1182/blood-2018-99-112310 · Cited by 12 · see citing works

Transplantation for therapy-related, TP53 -mutated myelodysplastic syndrome – not because we can, but because we should

Cutler, C. S. (2017) · Haematologica · doi:10.3324/haematol.2017.181180 · Cited by 10 · see citing works

Molecular predictors of post-transplant survival in acute myeloid leukemia

Qin, T., Wu, S., Zhao, H., Xu, K., Fu, H., Cheng, Z., Pang, Y., Han, Y., Chen, L., Wang, C., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0027-6 · Cited by 9 · see citing works

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G. M., Kadia, T. M., Daver, N. G., Ohanian, M. N., Dinardo, C. D., et al. (2018) · Blood · doi:10.1182/blood-2018-99-115367 · Cited by 9 · see citing works

Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype

Sallman, D. A., McLemore, A. F., Komrokji, R. S., McGraw, K. L., Geyer, S. M., Eksioglu, E. A., Ali, N. E. A., Lancet, J. E., Wei, S., Padron, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.423.423 · Cited by 6 · see citing works

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Dennis, M. W., Hills, R. K., Thomas, I., Gupta, S., Panoskaltsis, N., Copland, M., Burnett, A. K., & Russell, N. H. (2016) · Blood · doi:10.1182/blood.v128.22.2827.2827 · Cited by 3 · see citing works

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465 · see citing works

Advances in acute myeloid leukemia

Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 455 · see citing works

Unified classification and risk-stratification in Acute Myeloid Leukemia

Tazi, Y., Ossa, J. A., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S. D., Pradat, Y., Johnson, S. J., Hills, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32103-8 · Cited by 195 · see citing works

TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works

Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161 · see citing works

A concise review on the molecular genetics of acute myeloid leukemia

Padmakumar, D., Chandraprabha, V. R., Gopinath, P., Devi, A. R. T. V., Anitha, G. R. J., Sreelatha, M. M., Padmakumar, A., & Sreedharan, H. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106727 · Cited by 81 · see citing works

What have we learned about TP53-mutated acute myeloid leukemia?

Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 83 · see citing works

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01417-5 · Cited by 76 · see citing works

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning

Eckardt, J., Röllig, C., Metzeler, K. H., Krämer, M., Stasik, S., Georgi, J.-A., Heisig, P., Spiekermann, K., Krug, U. O., Braess, J., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280027 · Cited by 53 · see citing works

Interplay of <i>TP53</i> allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53 · see citing works

Explainable artificial intelligence for precision medicine in acute myeloid leukemia

Gimeno, M., José‐Eneriz, E. S., Villar, S., Agirre, X., Prósper, F., Rubio, A., & Carazo, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977358 · Cited by 50 · see citing works

How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines

Chaer, F. E., Hourigan, C. S., & Zeidan, A. M. (2023) · Blood · doi:10.1182/blood.2022017808 · Cited by 51 · see citing works

Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment

Peroni, E., Randi, M. L., Rosato, A., & Cagnin, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02841-8 · Cited by 47 · see citing works

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 38 · see citing works

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia

Sallman, D. A. (2020) · Haematologica · doi:10.3324/haematol.2020.249060 · Cited by 37 · see citing works

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Roloff, G. W., Odenike, O. M., Bajel, A. R., Wei, A. H., Foley, N. C., & Uy, G. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349605 · Cited by 36 · see citing works

DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients

Hu, L., Gao, Y., Shi, Z., Liu, Y., Zhao, J., Xiao, Z., Lou, J., Xu, Q., & Tong, X. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.122 · Cited by 32 · see citing works

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS

Stengel, A., Haferlach, T., Baer, C. R., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009100 · Cited by 30 · see citing works

Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure

Pasquer, H., Tostain, M., Kaci, N., Roux, B., & Benajiba, L. (2021) · Cancers · doi:10.3390/cancers13040748 · Cited by 28 · see citing works

Advances in therapeutic options for newly diagnosed, high-risk AML patients

Doucette, K., Karp, J. E., & Lai, C. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001138 · Cited by 24 · see citing works

Targeting Apoptosis in AML: Where Do We Stand?

Krawiec, K. M., Strzałka, P., Czemerska, M., Wiśnik, A., Zawlik, I., Wierzbowska, A., & Pluta, A. (2022) · Cancers · doi:10.3390/cancers14204995 · Cited by 26 · see citing works

The promise of macrophage directed checkpoint inhibitors in myeloid malignancies

Swoboda, D. M., & Sallman, D. A. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101221 · Cited by 25 · see citing works

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Tahir, S. K., Calvo, E., Carneiro, B. A., Yuda, J., Shreenivas, A. V., Jongen‐Lavrencic, M., Gort, E. H., Ishizawa, K., Morillo, D., Biesdorf, C., et al. (2023) · Blood · doi:10.1182/blood.2022017333 · Cited by 24 · see citing works

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 22 · see citing works

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

Daver, N. G., Iqbal, S., Huang, J. C., Renard, C., Lin, J., Pan, Y., Williamson, M., & Ramsingh, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26941 · Cited by 22 · see citing works

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

Niparuck, P., Police, P., Noikongdee, P., Siriputtanapong, K., Limsuwanachot, N., Rerkamnuaychoke, B., Chuncharunee, S., & Siriboonpiputtana, T. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01162-8 · Cited by 22 · see citing works

Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes

Huang, L., Lin, L., Fu, X., & Meng, C. (2021) · PeerJ · doi:10.7717/peerj.11968 · Cited by 21 · see citing works

Progress toward Better Treatment of Therapy-Related AML

Kotsiafti, A., Giannakas, K., Christoforou, P., & Liapis, K. (2023) · Cancers · doi:10.3390/cancers15061658 · Cited by 17 · see citing works

Searching for a signature involving 10 genes to predict the survival of patients with acute myelocytic leukemia through a combined multi-omics analysis

Zhuang, H., Chen, Y., Sheng, X., Hong, L., Gao, R., & Zhuang, X. (2020) · PeerJ · doi:10.7717/peerj.9437 · Cited by 16 · see citing works

Zebrafish models of acute leukemias: Current models and future directions

Molina, B., Chavez, J., & Grainger, S. J. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.400 · Cited by 15 · see citing works

Arsenic concentration in topsoil of central Chile is associated with aberrant methylation of P53 gene in human blood cells: a cross-sectional study

Eva Madrid, A., González, I., Muñoz, S., Rejas, C., Cardemil, F., Martínez, F. T., Cortes, J. P., Berasaluce, M., & Párraga, M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19085-2 · Cited by 13 · see citing works

The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis

Qin, G., & Han, X. (2022) · Transfusion Medicine and Hemotherapy · doi:10.1159/000526174 · Cited by 11 · see citing works

New Treatment Options for Older Patients with Acute Myeloid Leukemia

Saxena, K., & Konopleva, M. Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00841-4 · Cited by 11 · see citing works

m 6 A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia

Liao, X., Chen, L., Liu, J., Hu, H., Hou, D., You, R., Wang, X., & Huang, H. (2022) · Epigenetics · doi:10.1080/15592294.2022.2160134 · Cited by 11 · see citing works

Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia

Chandra, D. J., Lachowiez, C. A., & Loghavi, S. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101156 · Cited by 10 · see citing works

Comprehensive analysis of m 6 A methylome alterations after azacytidine plus venetoclax treatment for acute myeloid leukemia by nanopore sequencing

Zhang, Z., Zhang, L., Li, J., Feng, R., Li, C., Liu, Y., Sun, G., Xiao, F., & Zhang, C. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.02.029 · Cited by 9 · see citing works

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies

Kruer, T. L., Quintana, A., Newman, H., Ferrall‐Fairbanks, M. C., Zhang, L., McLemore, A. F., Neupane, S., Yang, Q., Ben-Crentsil, N. A., Balasis, M. E., et al. (2025) · Blood · doi:10.1182/blood.2025028803 · Cited by 10 · see citing works

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Czegle, I., Gray, A. L., Wang, M., Liu, Y., Wang, J., & Wappler-Guzzetta, E. A. (2021) · Life · doi:10.3390/life11121351 · Cited by 10 · see citing works

Recommendations for laboratory testing of UK patients with acute myeloid leukaemia

Mehta, P., Telford, N., Wragg, C., Dillon, R. J., Freeman, S. D., Finnegan, D. P. J., Hamblin, A. D., Copland, M., & Knapper, S. (2022) · British Journal of Haematology · doi:10.1111/bjh.18516 · Cited by 9 · see citing works

Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia

Yoshida, S. Y., Onozawa, M., Miyashita, N., Kimura, H., Takahashi, S., Yokoyama, S., Matsukawa, T., Hirabayashi, S., Mori, A., Hidaka, D., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03522-6 · Cited by 8 · see citing works

Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia

Shi, L., Huang, R., & Lai, Y. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00975-2 · Cited by 7 · see citing works

Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for li-fraumeni syndrome

Wang, Y., Wang, Z., Cormier, R., Miao, J., Li, R., Wettere, A. V., Guo, H., Tăbăran, F., O'Sullivan, M., Carlson, T., et al. (2021) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_18_21 · Cited by 7 · see citing works

CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia

Li, Q., Liang, C., Xu, X., Zhang, C., Cao, W., Wang, M., Jiang, Z., Xing, H., & Yu, J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2064986 · Cited by 7 · see citing works

Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach

Wei, J., Ji, K., Zhang, Y., Zhang, J., Wu, X., Ji, X., Zhou, K., Yang, X., Lu, H., Wang, A., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00892-9 · Cited by 7 · see citing works

High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia

Yang, S., Liu, W., Peng, J., Xu, Y., Liu, Y., Li, Y., Peng, M., Ouyang, Z., Chen, C., & Liu, E. (2021) · Journal of Cancer · doi:10.7150/jca.50472 · Cited by 7 · see citing works

Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., & Diamantopoulos, P. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041082 · Cited by 5 · see citing works

Precision Medicine in Myeloid Malignancies: Hype or Hope?

Banskota, S. U., Khanal, N., Marar, R. I., Dhakal, P., & Bhatt, V. R. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00674-4 · Cited by 6 · see citing works

Identification of prognostic and driver gene mutations in acute myeloid leukemia by a bioinformatics analysis

Li, L., Ruan, J., Zhang, N., Dai, J. L., Xu, X., Tian, X., & Hu, J. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-587 · Cited by 6 · see citing works

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells

Valdez, B. C., Yuan, B., Murray, D. L., Ramdial, J., Popat, U., Nieto, Y. L., & Andersson, B. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28563 · Cited by 5 · see citing works

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations

Koolivand, Z., Bahreini, F., Rayzan, E., & Rezaei, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41355 · Cited by 6 · see citing works

p53 immunohistochemistry staining is a rapid screening method for TP53 mutation in myeloid malignancies suitable for integration into routine diagnostic laboratory practice

Nelles, R., Tallack, M. R., Tate, C., Hunt, S., Aung, H., Henden, A. S., Jones, L. V., & Seymour, L. (2025) · Pathology · doi:10.1016/j.pathol.2024.11.011 · Cited by 5 · see citing works

Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia

Wang, Y., Zhou, W., McReynolds, L. J., Katki, H. A., Griffiths, E. A., Thota, S., Machiela, M. J., Yeager, M., McCarthy, P. L., Pasquini, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94539-0 · Cited by 5 · see citing works

EDUCACIÓN PARA EL BILINGÜISMO EN CONTEXTO MONOLINGÜE: DOS LENGUAS CONECTADAS DESDE EL CURRÍCULO

Ordóñez, C. L. (2010) · Elia · Cited by 5 · see citing works

Mutation-Driven Therapy in MDS

Swoboda, D. M., & Sallman, D. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00554-4 · Cited by 5 · see citing works

Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?

Ferrara, F., & Picardi, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1715207 · Cited by 5 · see citing works

Recruiting TP53 to target chronic myeloid leukemia stem cells

Grant, S. (2020) · Haematologica · doi:10.3324/haematol.2019.246306 · Cited by 5 · see citing works

What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias

Pizzi, M., Gurrieri, C., & Orazi, A. (2023) · Hemato · doi:10.3390/hemato4020011 · Cited by 4 · see citing works

Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review

Ma, C., Lang, H., Chen, Y., Yang, L., Wang, C., Han, L., Chen, X., & Ma, W. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001594 · Cited by 4 · see citing works

Evaluating targeted therapies in older patients with TP53 -mutated AML

Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4 · see citing works

Overall survival in TP53-mutated AML and MDS

Puzo, C. J., Hager, K. M., Rinder, H. M., Weinberg, O. K., & Siddon, A. J. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06054-7 · Cited by 4 · see citing works

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies

Yang, G., Williams, S. A., He, F. C., He, Y., McIntyre, K., Beckman, A. K., Nelson, A., & Yohe, S. L. (2024) · Pathology · doi:10.1016/j.pathol.2023.11.009 · Cited by 4 · see citing works

Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System

Selvaraju, K., Lotfi, K., Gubat, J., Miquel, M., Nilsson, A., Hill, J., Jensen, L. D., Linder, S. T., & D’Arcy, P. (2021) · Biomolecules · doi:10.3390/biom11091339 · Cited by 4 · see citing works

Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations

Gholizadeh, E., Zangene, E., Parsons, A., Kontro, M., Heckman, C. A., & Jafari, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118647 · Cited by 3 · see citing works

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Eisenmann, E. D., Swords, R. T., Huang, Y., Orwick, S. J., Buelow, D. R., Abbott, N., Phelps, M. A., Zeidner, J. F., Foster, M. C., Lin, T. L., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0091 · Cited by 3 · see citing works

Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia

Makowka, P., Stolp, V., Stoschek, K., & Serve, H. L. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0288 · Cited by 3 · see citing works

Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights

Wang, L., Gao, H., Fu, Q., Jiang, Q., Jiang, H., Wang, Y., Xu, L., Zhang, X., Huang, X., & Tang, F. (2025) · British Journal of Haematology · doi:10.1111/bjh.70271 · Cited by 2 · see citing works

Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis

Chang, G., Gao, H., Wei, Y., Fu, Q., Jiang, Q., Jiang, H., Xu, L., Zhang, X., Huang, X., & Tang, F. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108187 · Cited by 2 · see citing works

TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition

Spinella, J.-F., Chagraoui, J., Boivin, I., Richard‐Carpentier, G., Moison, C., Mayotte, N., Béliveau, F., Lavallée, V., Hébert, J., & Sauvageau, G. (2026) · Science Advances · doi:10.1126/sciadv.aed7122 · Cited by 2 · see citing works

SNAI1: a key modulator of survival in lung squamous cell carcinoma and its association with metastasis

Li, B., & Li, R. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-03044-8 · Cited by 2 · see citing works

Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy

Yu, W., Kong, J., Zheng, F., Mo, X., Zhang, X., Xu, L., Zhang, Y., Sun, Y., Jin, J., Huang, X.-J., et al. (2024) · Hematology · doi:10.1080/16078454.2024.2418653 · Cited by 2 · see citing works

Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé

Szakács, Z., & Alizadeh, H. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00151 · Cited by 2 · see citing works

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities

Chen, Y., Zheng, J., Qiu, Y., Wu, Z., Luo, X., Zhu, L.-F., Wu, Y. C., & Lin, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1294037 · Cited by 1 · see citing works

Cancer as a Disease of Defective Cell Cycle Checkpoint Function

Jackson, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-32573-1_3 · Cited by 1 · see citing works

Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: potential for therapeutic intervention?

Schwaller, J. (2020) · Haematologica · doi:10.3324/haematol.2019.246348 · Cited by 1 · see citing works

Introduction to Cancer Treatment

Zonouzi, S. K., Razi, S., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_216-1 · Cited by 1 · see citing works

Comprehensive analysis of the landscape characteristics of m6A regulators in acute myeloid leukemiaPreprint

Liao, X., Chen, L., Liu, J., Hu, H., Hou, D., You, R., Wang, X., & Huang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1511744/v1 · Cited by 1 · see citing works

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaPreprint

Posey, R. R., Lee, J. D., Clohessy, S., Mendez, L., & Pandolfi, P. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002774

Treatment Algorithms for Higher-Risk Disease

Hambley, B. C., & Dezern, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_9

Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients

Récher, C. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_12

Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie

Krämer, A., & Thiede, C. (2022) · Die Onkologie · doi:10.1007/s00761-022-01183-y

Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemiaPreprint

Shi, L., Huang, R., & Lai, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-481823/v1

Peer Review #2 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/2

Peer Review #4 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.2)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.2/reviews/4

Peer Review #3 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.2)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.2/reviews/3

Peer Review #3 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/3

TP53 Mutation in Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic SyndromePreprint

Niparuck, P., Police, P., Noikongdee, P., Siriputtanapong, K., Limsuwanachot, N., Rerkamnuaychoke, B., Chuncharunee, S., & Siriboonpiputtana, T. (2021) · Research Square · doi:10.21203/rs.3.rs-148593/v1

Peer Review #4 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/4

Peer Review #1 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"

(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/1

Pathogenetic value of TP53 point mutations in adult acute myeloid leukemia patients

Vinogradov, A. V., Rezaykin, A. V., Литвинова, Д. В., Loboda, A., Sazonov, S. V., & Sergeev, A. G. (2020) · Russian Journal of Immunology · doi:10.46235/1028-7221-264-pvo

Interpretable precision medicine for acute myeloid leukemia

Gimeno, M. (2023) · doi:10.15581/10171/65641

Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

Fu, Y., Su, L., Li, Y., & Tan, Y.-H. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00933-x

Additional file 2 of Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia

Shi, L., Huang, R., & Lai, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14594481

Azvudine exhibits potent differentiation-inducing effect by targeting the TERT/p21 axis in acute myeloid leukemia

Kwon, C.-S., Lee, J., Jeon, B.-E., Kim, T., Lee, S. H., Shin, H., & Kim, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118215

Introduction to Cancer Treatment

Zonouzi, S. K., Razi, S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_216

Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients

Alzetta, D., Cavattoni, I., & Mosna, F. (2025) · Cancers · doi:10.3390/cancers17203285

Additional file 1 of Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia

Shi, L., Huang, R., & Lai, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14594478

Additional file 3 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617344

Additional file 2 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617341

Additional file 1 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617338

TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches

Deshpande, S., Li, W. F., Song, J., Forsberg, M., Cerchione, C., Martinelli, G., & Konopleva, M. Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1735418

What have we learned about TP53-mutated acute myeloid leukemia?

Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 83 · see citing works

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 50 · see citing works

Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics

Asghari, H. H., & Talati, C. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000568 · Cited by 7 · see citing works

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 28 · see citing works

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Molica, M., Mazzone, C., Niscola, P., & de Fabritiis, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610820 · Cited by 71 · see citing works